The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics
 
James D. Battiste
No Relationships to Disclose
 
Samuel Aaron Goldlust
Stock and Other Ownership Interests - COTA
Honoraria - Bristol-Myers Squibb; Novocure; Tocagen; Wex Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Cortice Biosciences; Novocure; Tocagen; Wex Pharmaceuticals
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); ImmunoCellular Therapeutics (Inst); Karyopharm Therapeutics (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Tocagen (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Boston Biomedical; Novocure; Tocagen; Wex Pharmaceuticals
 
James Stuart Garner
Employment - Kazia Therapeutics
Leadership - Kazia Therapeutics
Stock and Other Ownership Interests - Kazia Therapeutics
 
Jeremy Andrew Simpson
Employment - Kazia Therapeutics
Stock and Other Ownership Interests - Bionomics; Kazia Therapeutics
 
Jelle Kijlstra
Employment - Covance
Stock and Other Ownership Interests - Covance
 
Alan Olivero
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
Consulting or Advisory Role - Aduro Biotech; Genentech/Roche; Imugene; Kazia Therapeutics; ORIC Pharmaceuticals
Research Funding - Genentech/Roche
Patents, Royalties, Other Intellectual Property - I have patents from my employment with Genentech/Roche
Travel, Accommodations, Expenses - Kazia Therapeutics
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research